J&J Medical Connect
Immunology
Immunology

Congress Materials – Elevate Derm Summer Congress (Elevate-Derm 2026)

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Adolescents with Psoriasis in the United States: Current Treatment Landscape and Unmet Needs

Jennifer Soung, Linda Stein Gold, Nina Trenkler, Melina Taylor, Laurie Conklin, Jensen Lewis, Timothy Fitzgerald, Wesley Peters, Ya-Wen Yang, Guo Li, Mona Shahriari


This document will be available after July 29th 2026

Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis

Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Andrew E. Pink, Joseph Cafone, Bassey Effiom Edem, Ofelia Reyes-Servin, Shu Li, Ya-Wen Yang, Mark G. Lebwohl


This document will be available after July 29th 2026

Durability of Icotrokinra (Targeted Oral Peptide) Effects in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study

Jennifer Soung, Mark G. Lebwohl, Adelaide Hebert, Andrew E. Pink, Yuling Shi, Megan Miller-Kassamali, Joseph Cafone, Jingzhi Jiang, Shu Li, Ya-Wen Yang, Lawrence F. Eichenfield


This document will be available after July 29th 2026

Early and Durable Improvements in Patient-Reported Outcomes With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Study

Jennifer Soung, Mark G. Lebwohl, Adelaide Hebert, Andrew E. Pink, H. Chih-ho Hong, Charles Iaconangelo, Joseph Cafone, Jingzhi Jiang, Shu Li, Ya-Wen Yang, Lawrence F. Eichenfield


This document will be available after July 29th 2026

Robust Icotrokinra Systemic and Skin Pharmacodynamic Effects Versus Deucravacitinib in Patients With Moderate-to-Severe Plaque Psoriasis: Results From Phase 3, ICONIC-ADVANCE-1 Study

APJ Van den Heuvel, H Li, E Chen, J Angsana, ME Polak, N Yum, C DeKlotz, N Sabins, L Stein Gold, AG Cantero, RB Warren


This document will be available after July 29th 2026

Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of 4 Phase 3 Placebo-Controlled Trials

Jennifer Soung, April W. Armstrong, Ronald B. Vender, Josep Riera-Monroig, Michael Sebastian, Ofelia Reyes-Servin, Bassey Effiom Edem, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Linda Stein Gold


This document will be available after July 29th 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.